<DOC>
	<DOCNO>NCT02408705</DOCNO>
	<brief_summary>Each subject allocate 2 period 3 month daily dose either liraglutide ( 1.2 mg ) placebo treatment ( random sequence ) add usual intensive insulin treatment . Wash-out period treatment 1 month . The trial divide follow period : - Screening - Treatment period 1 - Washout period - Treatment period 2 - Follow Visit Mixed Meal Tolerance Test ( MMTT ) enrich paracetamol : At begin end period MMTT ( Fortimel complete ) enrich paracetamol perform assess remain beta-cell function via obtain maximal plasma C-peptide level well gastric empty . Experimental / Hypoglycaemic clamp : At end period ( Visit 8 , 15 ) hypoglycaemic clamp perform . After subject complete MMTT day 1 , subject stay clinical unit prepare hypoglycaemic clamp variable insulin infusion intravenously order obtain steady state plasma glucose ( PG ) level 5.5 mmol/L overnight approximately 08:00 . At 05:00 hour 10 % - [ 6,6-2H2 ] glucose solution give i.v . prim ( 9.6mg/kg/min ) one minute constant ( 0.08 mg/kg/min ) infusion last blood sample plateau 4.0 mmol/L perform . At 08:00 hour morning day 2 , insulin infusion increase 1.5 mU/kg/min subject PG keep plateau 5.5 mmol/L control variable intravenous infusion glucose ( 10 % glucose enrich 4mg [ 6,6-2H2 ] glucose /ml ) one hour . Afterwards , PG allow fall plateau 3.5 mmol/L , nadir 2.5 mmol/L , blood glucose 4.0 mmol/L finally back level 5.5 mmol/L safety reason . Blood sample measurement [ 6,6-2H2 ] glucose , glucagon , insulin , counterregulatory hormone , lactate , free fatty acid , glycerol , vital sign , hypoglycaemic symptom questionnaire hypoglycaemic awareness perform PG plateau .</brief_summary>
	<brief_title>Investigating Effect Liraglutide Endogenous Glucose Production During Tye 1 Diabetes Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>1 . Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial 2 . Type 1 diabetes mellitus diagnose ( include I III ) : I. history type 1 diabetes mellitus manifestation acute hyperglycaemia ketonuria II . positive result least one four islet antibody ( glutamic acid decarboxylase , protein tyrosine phosphatase , zinc transporter 8 , islet cell antibody ) III . residual basal fast Cpeptide ≥ 0.1 nmol/L 3 . Male female , age 18 64 year ( inclusive ) 4 . Body mass index ( BMI ) 20.0 25.0 kg/m2 ( inclusive ) 5 . HbA1c 42 80 mmol/mol ( 6.09.5 % ) 6 . Treated daily insulin injection continuous s.c. insulin infusion ( CSII ) ≥ 1 month . Stable insulin dose judge investigator 1 . Known suspected hypersensitivity trial product ( ) relate product 2 . Use liraglutide exenatide within 3 month screen 3 . Severe hypoglycaemia within 1 month screen 4 . Hypoglycaemia unawareness judge Investigator hospitalisation diabetic ketoacidosis previous 2 month 5 . Clinically significant abnormal haematology , biochemistry , lipid , urinalysis coagulation screening test , judge investigator follow laboratory safety result : Aspartate transaminase ( =AST ) , alanine aminotransferase ( =ALT ) , lipase , alkaline phosphatase &gt; 2.0 time upper limit reference range ( ULN ) Haemoglobin &lt; 8.0 mmol/L ( male ) &lt; 6.4 mmol/L ( female ) , total leukocyte count &lt; 3.0 x 109/L , thrombocytes &lt; 100 x 109/L Serum creatinine level ≥ 126 μmol/L ( male ) ≥ 111 μmol/L ( female ) Amylase outside normal range 6 . Screening calcitonin &gt; 50 ng/L 7 . Personal history nonfamilial medullary thyroid carcinoma 8 . History chronic idiopathic acute pancreatitis Suffer history life threaten disease ( e.g . cancer except basal cell skin cancer squamous cell skin cancer ) , clinically significant respiratory , metabolic , renal , hepatic , gastrointestinal , endocrinological ( exception diabetes mellitus euthyroid struma ) , haematological , dermatological , venereal , neurological , psychiatric disease major disorder judge investigator . 9 . Proliferative retinopathy maculopathy and/or severe neuropathy , particular autonomic neuropathy , judge investigator . 10 . Any disease condition , opinion investigator , would represent unacceptable risk subject 's safety . 11 . Any condition would interfere trial participation evaluation result , judged investigator . 12 . Female childbearing potential pregnant , breastfeed intend become pregnant use adequate contraceptive method ( adequate contraceptive method include sterilisation , hormonal intrauterine device , oral contraceptive , sexual abstinence vasectomise partner ) . 13 . Severe acute and/or chronic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Endogenous Glucose Production</keyword>
	<keyword>Hypoglycemic clamp</keyword>
	<keyword>Tracer Tracee Technique</keyword>
	<keyword>Type 1 diabetes mellitus</keyword>
</DOC>